An influential American criticized the hospital Multaq

The last drug against heart rhythm disorders produced by Sanofi-Aventis, the Multaq, is far from unanimous. A report from the Institute of Cardiology at Cedars-Sinai in Los Angeles concluded Monday that he was ineffective. It would be even less effective than 50% compared to the generic name already used, amiodarone.

The report, based on a study of 30,000 patients treated with Multaq, indicating that the drug "should only be used as an agent of the second or third line ' cheap payday advance.

Basically, the Multaq was developed to reduce side effects of the credit, which ultimately is not the case, said the report's lead author Dr. Sabnjay Kaul. He also believes that amiodarone has an advantage in cost compared to Multaq.What stopping just over the reputation of the drug from Sanofi-Aventis, also criticized in France.

Read also:

"Sanofi-Aventis drug criticized on its future star

• G20 disagreements on tax credit
• Generali: Bernheim prepares his "response"
• Theolia heavily penalized Exchange
• Four years in prison need against Kerviel
• Around the world, the administration in the diet